TB vaccines in clinical development

TB vaccines in clinical development

Mostrar otras versiones (2)

The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 - 24 April 2015, brought together a wide and diverse community involved in tuberculosis vaccine research and development to discuss the current status of, and future directions for this critical effort. This paper summarizes t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ginsberg, A, Ruhwald, M, Mearns, H, Mcshane, H
Formato:	Journal article
Publicado:	Elsevier 2016

Ejemplares similares

TB vaccines in clinical development
por: Ginsberg, AM, et al.
Publicado: (2016)

TB vaccines in clinical development
por: Ginsburg, A, et al.
Publicado: (2016)

TB vaccine development: where are we and why is it so difficult?
por: Wilkie, M, et al.
Publicado: (2014)

A review of clinical models for the evaluation of human TB vaccines.
por: O'Shea, M, et al.
Publicado: (2016)

Progress and challenges in TB vaccine development
por: Voss, G, et al.
Publicado: (2018)

Towards new TB vaccines
por: Brazier, B, et al.
Publicado: (2020)

Need for more TB vaccine field sites.
por: Mcshane, H
Publicado: (2009)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
por: Mcshane, H
Publicado: (2008)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
por: Minassian, A, et al.
Publicado: (2011)

New TB vaccine granted orphan drug status.
por: Lang, T, et al.
Publicado: (2005)

A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
por: Pepponi, I, et al.
Publicado: (2017)

Co-infection with HIV and TB: double trouble.
por: Mcshane, H
Publicado: (2005)

Progress and challenges in TB vaccine development [version 1; referees: 2 approved]
por: Gerald Voss, et al.
Publicado: (2018-02-01)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
por: McShane, H, et al.
Publicado: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
por: McShane, H, et al.
Publicado: (2014)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
por: Thomas, Z, et al.
Publicado: (2014)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
por: Angela M Minassian, et al.
Publicado: (2011-01-01)

Identification and evaluation of novel protective antigens for the development of a candidate TB subunit vaccine
por: Stylianou, E, et al.
Publicado: (2018)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
por: Pathan, A, et al.
Publicado: (2012)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
por: Sander, C, et al.
Publicado: (2005)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
por: Odutola, A, et al.
Publicado: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
por: Odutola, A, et al.
Publicado: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, A, et al.
Publicado: (2012)

Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents
por: Rustomjee, R, et al.
Publicado: (2013)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
por: Tameris, M, et al.
Publicado: (2014)

Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents.
por: Rustomjee, R, et al.
Publicado: (2013)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
por: Whelan, K, et al.
Publicado: (2009)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
por: Tameris, M, et al.
Publicado: (2014)

Clinical Development of New TB Vaccines: Recent Advances and Next Steps
por: Mark Hatherill, et al.
Publicado: (2020-01-01)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
por: Owiafe, P, et al.
Publicado: (2012)

Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
por: Pinpathomrat, N, et al.
Publicado: (2021)

Tuberculosis vaccines in clinical trials.
por: Rowland, R, et al.
Publicado: (2011)

Developing an improved vaccine against tuberculosis.
por: Mcshane, H
Publicado: (2004)

Bayesian Augmented Clinical Trials in TB Therapeutic Vaccination
por: Dimitrios Kiagias, et al.
Publicado: (2021-10-01)

Experimental animal modelling for TB vaccine development
por: Pere-Joan Cardona, et al.
Publicado: (2017-03-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
por: Harris, S, et al.
Publicado: (2011)

Insights and challenges in tuberculosis vaccine development
por: McShane, H
Publicado: (2019)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
por: Meyer, J, et al.
Publicado: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
por: Meyer, J, et al.
Publicado: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
por: Riste, M, et al.
Publicado: (2021)